In the frame of a collaborative drug development project scientists from Biomedcode and BSRC Al. Fleming using bioinformatics tools, have repurposed the neuroleptic drug amisulpride for the reversal of the pathogenic expression signature of synovial fibroblasts and the treatment of arthritis pathology.
Published in JCI Insight 2023 May 8;8(9):e165024. doi: 10.1172/jci.insight.165024.
In this paper the anti-TNF/IL6 bispecific nanobody is tested on the Tg197 arthritis model.
Published in Science Translational Medicine 2023 Feb;15(681):eabq4419. doi: 10.1126/scitranslmed.abq4419.
Published in Scientific Reports 2022 Oct 28;12(1):18189. doi: 10.1038/s41598-022-22734-8
Biomedcode is pleased to announce that, the T2EDK program -development of a bronchoscopic biopsies-on-chip (BioOnChip) platform for immunotherapy drug screening in non-small cell lung cancer- initiated in collaboration with the BSRC Al. Fleming researcher M. Tsoumakidou, the Department of Computer Science and Biomedical Informatics of the University of Thessaly and the Pulmonary Clinic of the University of Ioannina has been financed by the European Union – Next Generation EU and the National Recovery and Resilience Plan Greece 2.0 funds. BioOnChip aims to explore the applicability of an innovative 3D microfluidic microculture, i.e. tumor-on-chip, in predicting real-time responses to PD1-blockade in NSCLC patients, that, if efficient, might have important socioeconomic impact.
The project is implemented within the framework of the National Recovery and Resilience Plan “Greece 2.0” with funding from the European Union – NextGenerationEU
In this recent paper, Ishiwatari-Ogata et all, using the Tg197 mouse model of arthritis, show that Ozoralizumab, a trivalent, bispecific NANOBODY compound offers anti-arthritis efficacy even in the secondary-failure phase.
Published in Frontiers in Immunology 2022 Feb 22;13:853008. doi: 10.3389/fimmu.2022.853008.
Our paper in Journal of Translational Medicine shows that combination of dasatinib and other kinase inhibitors with a subtherapeutic anti‐hTNF dose effectively treats arthritis pathology.
Published in Journal of Translational Medicine 2021 Apr 23;19(1):165. doi: 10.1186/s12967-021-02764-y.
Biomedcode has been recognized by the Pharma Tech Outlook magazine as one of the top 10 CROs of the year 2020. An interview with Biomedcode’s CEO and CSO is published in this month’s special edition on Europe’s CROs.
Biomedcode is excited to participate as one of the 63 European companies that have been selected to join the EUGATEWAY Healthcare and Medical Technologies Business Mission to Singapore on 8-11 December 2020. Due to the COVID-19 pandemic this will be a virtual event and we look forward to discussing with potential new partners and clients about future collaborations!
Pro-Infliximab provided equivalent therapeutic efficacy to Infliximab while maintaining mouse immunity against Listeria infection, leading to a significantly higher survival rate (71%) than that of the Infliximab treatment group (0%).
Published in PLoS Biology 2019 Jun 13;17(6):e3000286. doi: 10.1371/journal.pbio.3000286.